Lantern Pharma Enrolls First Patient in Taiwan for Phase 2 HARMONIC™ Trial of LP-300 in Never-Smoker NSCLC
Lantern Pharma Inc. (NASDAQ: LTRN), an AI-driven company developing targeted cancer therapies through its proprietary RADR® AI platform, announced today the enrollment and dosing of the first patient in Taiwan for its Phase 2 HARMONIC™ clinical trial. The trial is…
SABCS 2024: New Data on Breast Cancer Index® Test for Minimal Recurrence Risk
Four new studies on the Breast Cancer Index (BCI) test will be presented at the 2024 San Antonio Breast Cancer Symposium (SABCS). Among these, preliminary data will be shared exploring the potential of the BCI test to identify postmenopausal women…
Health Canada Approves Celltrion’s Omlyclo™ (CT-P39), Canada’s First Omalizumab Biosimilar
Celltrion announced today that Health Canada has approved Omlyclo™, a biosimilar referencing Xolair®. Omlyclo™ is now approved for the treatment of adults and adolescents with chronic idiopathic urticaria (CIU), also known as chronic spontaneous urticaria (CSU), as well as for…
Intelliguard and Codonics Partner to Enhance Patient Safety
Intelliguard, a leading provider of RFID-enabled medication management and data-intelligence solutions, has announced a strategic partnership with Codonics, a global leader in healthcare technology focused on patient safety. This collaboration integrates Intelliguard’s Mira Care Station with Codonics’ Safe Label System…
DNAnexus and Panomics Partner to Provide Multi-omics Data Solutions for Biopharma
DNAnexus, Inc., a leader in precision health data platforms, and Panomics, Inc., specializing in AI-powered omics data management and discovery for biopharma, have announced a strategic collaboration. This partnership will deliver biopharma organizations a comprehensive solution for multi-omics data management…
Updated Data on MaaT013 in Early Access Program Presented at ASH 2024
MaaT Pharma will host a KOL webinar on December 17th, 2024, to discuss the data and the unmet medical need in acute Graft-versus-Host Disease (aGvHD) – Register here. Key Results: MaaT Pharma (EURONEXT: MAAT), a clinical-stage biotechnology company specializing in…
Five-Year Results Confirm Genentech’s Polivy Combo as New Standard for Untreated Aggressive Lymphoma
Genentech, a member of the Roche Group, today announced five-year follow-up data from the pivotal Phase III POLARIX study. The study evaluated Polivy® (polatuzumab vedotin-piiq) in combination with Rituxan® (rituximab), cyclophosphamide, doxorubicin, and prednisone (R-CHP) in patients with untreated diffuse…
Merck’s Zilovertamab Vedotin + R-CHP Shows 100% Complete Response in Phase 2 DLBCL Trial
Merck (NYSE: MRK), known as MSD outside the United States and Canada, has presented promising results from its Phase 2 waveLINE-007 trial at the 66th American Society of Hematology (ASH) Annual Meeting. The trial evaluated zilovertamab vedotin, an investigational antibody-drug…
ReAlta Life Sciences Presents Positive Preclinical Data for RLS-0071 in aGVHD at ASH Annual Meeting
ReAlta Life Sciences, Inc. (“ReAlta”), a clinical-stage biopharmaceutical company focused on rebalancing the inflammatory response to treat rare and acute inflammatory diseases, announced promising preclinical data for its lead asset, RLS-0071 (pegtarazimod), in acute Graft-versus-Host Disease (aGVHD). These findings will…
Epcoritamab Combination Therapy Shows High Response Rates in R/R Follicular Lymphoma
Genmab A/S has shared new results from the Phase 1b/2 EPCORE® NHL-2 trial evaluating epcoritamab, a T-cell engaging bispecific antibody, in combination with lenalidomide and rituximab (R2) for treating relapsed or refractory (R/R) follicular lymphoma (FL). The study demonstrated an…
Orca Bio Presents Clinical Results of Orca-Q® Without GvHD Prophylaxis at ASH 2024
Orca Bio, a late-stage biotechnology company focused on transforming patient care through high-precision cell therapy, presented clinical findings today at the 66th American Society of Hematology (ASH) Annual Meeting. The data highlights the use of Orca-Q, its investigational second-generation allogeneic…
New Results Show Donor Search Score Equalizes Transplant Outcomes at ASH 2024
The Blood and Marrow Transplant Clinical Trials Network (BMT CTN) will present new findings at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego. The data demonstrates that a donor search prognosis score enables physicians to expedite…